Morgan Stanley Maintains Overweight on Arrowhead Pharma, Raises Price Target to $120

Benzinga Newsdesk www.benzinga.com Positive 67.8%

Neg 0% Neu 0% Pos 67.8%

Morgan Stanley analyst Michael Ulz maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and raises the price target from $100 to $120.